Product Pipeline

•  Zerenex^TM 
   
  •  About Zerenex^TM 
  •  Market Opportunity 
  •  Development Status 
  •  Clinical Trials 
    - Phase II Dose Ranging Study 
    



•  KRX-0401 (Perifosine) 
   
  •  About KRX-0401 (Perifosine) 
  •  Pre-Clinical Data 
  •  Development Status 
  •  Clinical Trials 
    

Product candidate Target indication Development status KRX-0401 (perifosine) Multiple myeloma Colorectal cancer Multiple other forms of cancer Phase 3 ongoing, under SPA Phase 3 ongoing, under SPA Phase 2 trials ongoing ZerenexTM (ferric citrate) Hyperphosphatemia in patients with end-stage renal disease U.S. Phase 3 program ongoing under SPA; Japan Phase 2 complete by sublicensee (JT and Torii)

Copyright © 2010 by Keryx Biopharmaceuticals, Inc. Update Notice | Disclaimer | Contact Us

Disclaimer: These investigational drug products have not been approved by the US Food and Drug Administration for safety and effectiveness. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness